Search clinical trials for: LENALIDOMIDE (CC-5013)

Total 7386 results

Celgene

Completed

Study of the Safety and Efficacy of CC-5013 Treatment For Patients With Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States
Celgene

Completed

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Myelodysplastic Syndromes

United States, Germany
Celgene Corporation

Completed

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, Denmark, Australia, Belgium, Czech Republic, France, Germany, Greece, Italy, Netherlands, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Lenalidomide Maintenance in Plasma Cell Myeloma

Plasma Cell Myeloma

United States
Celgene Corporation
Prologue Research International

Terminated

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Pancreatic Cancer

United States
Memorial Sloan Kettering Cancer Center
Weill Medical College of Cornell University; Celgene Corporation; University... and other collaborators

Completed

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma

Multiple Myeloma | Non-Hodgkin's Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Columbia University; Montefiore Medical Center; Weill Medical College of Cornell... and other collaborators

Completed

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

Multiple Myeloma

United States
M.D. Anderson Cancer Center
Celgene Corporation

Completed

Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma

Melanoma

United States
Celgene

Completed

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Neoplasms

United States
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Recurrent Glioma

Brain and Central Nervous System Tumors

United States
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaborators

Terminated

CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Waldenstrom's Macroglobulinemia

United States
Celgene Corporation
Prologue Research International

Completed

Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
University of Arkansas

Completed

Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

Multiple Myeloma

United States
Celgene Corporation
Prologue Research International

Terminated

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

Ovarian Cancer

United States
Celgene

Completed

A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple Myeloma

Multiple Myeloma

Ukraine, Russian Federation
M.D. Anderson Cancer Center
Celgene Corporation

Completed

A Phase II Study of CC-5013 in Myelofibrosis

Myelofibrosis

United States
Celgene Corporation

Completed

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

Multiple Myeloma

United States
Celgene Corporation
Prologue Research International

Completed

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkins Lymphoma

United States
Celgene Corporation
Prologue Research International

Completed

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma

United States, Canada
Celgene

Completed

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States, Spain, Germany, France, Italy, Canada, United Kingdom
Celgene Corporation
Prologue Research International

Terminated

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Celgene

Completed

A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

Spain, United Kingdom, Switzerland, Australia, Israel, Italy, Poland, France, Belgium, Ireland, Austria, Germany, Ukraine, Greece, Sweden
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; H. Lee Moffitt...

Completed

Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
Celgene Corporation

Completed

A Study of Doxil, Vincristine and Decadron (DVd) +/ CC-5013 in Relapsed Refractory Multiple Myeloma (MM)

Multiple Myeloma

United States
Celgene Corporation

Completed

A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

Relapsed or Refractory Multiple Myeloma

Germany
Celgene

Terminated

A Study to Evaluate the Efficacy of Lenalidomide as Maintenance Therapy After Completion of First-line Combination Chemotherapy in Patients With Mantle Cell Lymphoma (MCL). (RENEW)

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, Germany, France, Czechia, Israel, Italy, Poland, Portugal, Puerto Rico, Russian Federation
Celgene

Completed

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial (EMERGE)

Mantle Cell Lymphoma

United States, France, Belgium, Austria, Israel, Singapore, Spain, United Kingdom, Hungary, Colombia, Germany, Italy, Turkey, Puerto Rico
University of Turin, Italy

Completed

Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma

Multiple Myeloma

Italy
Celgene Corporation

Completed

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Radiculopathy

United States
Celgene Corporation
Prologue Research International

Completed

A Study to Evaluate the Single-Agent Lenalidomide in Subjects With Recurrent Non-Small-Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
Mayo Clinic

Completed

Efficacy of CC-5013 (Revlimid or Lenalidomide) in Patients With Primary Systemic Amyloidosis

Amyloidosis

United States
Vaishali Sanchorawala
Celgene Corporation

Completed

CC-5013 With or Without Dexamethasone in Treating Patients With Primary Systemic Amyloidosis

Multiple Myeloma

United States
Celgene

Completed

CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Lymphoma | Small Intestine Cancer | Unspecified Adult Solid Tumor, Protocol Specific

United States
Celgene
Prologue Research International

Completed

Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy

Malignant Melanoma

United States
National Cancer Institute (NCI)

Completed

Lenalidomide and Radiation Therapy in High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas

High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma

United States
Celgene Corporation

Completed

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) (CRPS)

Complex Regional Pain Syndrome (RSD)

United States
University of Wuerzburg

Completed

Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma

Refractory Multiple Myeloma | Relapse

Germany
Celgene

Completed

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

Multiple Myeloma

China
Celgene

Completed

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
M.D. Anderson Cancer Center

Completed

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

Leukemia | CLL

United States
Celgene Corporation

Completed

A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.

Newly Diagnosed Multiple Myeloma

Spain, Netherlands, Austria, Australia, Italy, Russian Federation, United Kingdom, Israel, Belgium, Greece, Germany, Poland, Turkey, France, Denmark, Czech Republic, Belarus, Georgia, Ireland, Sweden, Switzerland, Ukraine
Celgene

Active, not recruiting

A Non-interventional,Observational Post Authorization Study of Patients With Multiple Myeloma Treated With Lenalidomide TR

Multiple Myeloma

Turkey
Celgene

Completed

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Myelodysplastic Syndrome

United States, Germany
Celgene Corporation

Completed

A Study to Evaluate CC-5013 in the Treatment of Adolescents and Adults With Moderately Severe Crohn's Disease

Crohn's Disease

France, United States, United Kingdom, Israel
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
Center for Primary Care and Public Health (Unisante)...
Swiss Tropical & Public Health Institute; Ifakara Health Institute; University... and other collaborators

Recruiting

Dynamic CDSA to Manage Sick Children in Tanzania (DYNAMIC-TZ)

Child Health

Tanzania
University Health Network, Toronto
Celgene Corporation

Completed

Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin Disease
Great Ormond Street Hospital for Children NHS Foundation...
Newcastle-upon-Tyne Hospitals NHS Trust

Completed

Treosulfan Pharmacokinetics in Children Undergoing Allogeneic HSCT (TreoPK)

Allogeneic Haematopoietic Stem Cell Transplantation

United Kingdom
Celgene Corporation
Prologue Research International

Completed

Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Multiple Myeloma

United States, Canada

Search clinical trials for: LENALIDOMIDE (CC-5013)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Vietnam

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations